Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Case Rep ; 18: 1048-1052, 2017 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-28966341

RESUMEN

BACKGROUND A rare variant of Guillain-Barré syndrome (GBS) consists of facial diplegia and paresthesia, but an even more rare association is with facial hemiplegia, similar to Bell's palsy. This case report is of this rare variant of GBS that was associated with IgG antibodies to galactocerebroside and phosphatidic acid. CASE REPORT A 54-year-old man presented with lower left facial palsy and paresthesia of his extremities, following an upper respiratory tract infection. Physical examination confirmed lower left facial palsy and paresthesia of his extremities with hyporeflexia of his lower limbs and sensory loss of all four extremities. The differential diagnosis was between a variant of GBS and Bell's palsy. Following initial treatment with glucocorticoids followed by intravenous immunoglobulin (IVIG), his sensory abnormalities resolved. Serum IgG antibodies to galactocerebroside and phosphatidic acid were positive in this patient, but not other antibodies to glycolipids or phospholipids were found. Five months following discharge from hospital, his left facial palsy had improved. CONCLUSIONS A case of a rare variant of GBS is presented with facial diplegia and paresthesia and with unilateral facial palsy. This rare variant of GBS may which may mimic Bell's palsy. In this case, IgG antibodies to galactocerebroside and phosphatidic acid were detected.


Asunto(s)
Anticuerpos/sangre , Parálisis Facial/etiología , Galactosilceramidas/inmunología , Síndrome de Guillain-Barré/diagnóstico , Parestesia/etiología , Ácidos Fosfatidicos/inmunología , Humanos , Inmunoglobulina G/sangre , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio
2.
Cephalalgia ; 37(9): 902-905, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27385490

RESUMEN

Introduction We report a case of cervicogenic headache caused by an intradural extramedullary tumor of the middle cervical spine, which has not previously been reported. Case presentation The patient was a 73-year-old male who visited a physician for a chief complaint of pain from the left lower jaw to the auricle and occipital region. The headache was induced with retroflexion of the neck. On cervical magnetic resonance imaging, an intradural extramedullary tumor was noted on the left side at the C4/5 level. The intradural tumor, which arose from the C5 nerve root, was excised and the pain was resolved. The pathological diagnosis was schwannoma. Conclusion Previously reported cases of spinal cord tumor-induced cervicogenic headache were due to upper cervical spinal tumors. This is the first report that a middle-lower cervical intradural extramedullary tumor caused cervicogenic headache.


Asunto(s)
Neurilemoma/complicaciones , Neoplasias del Sistema Nervioso Periférico/complicaciones , Cefalea Postraumática/etiología , Raíces Nerviosas Espinales/patología , Anciano , Vértebras Cervicales , Humanos , Masculino
4.
Rinsho Shinkeigaku ; 45(5): 390-3, 2005 May.
Artículo en Japonés | MEDLINE | ID: mdl-15960180

RESUMEN

Hemiparkinsonism-hemiatrophy syndrome (HPHA) is a rare form of parkinsonism, characterized by unilateral parkinsonism, ipsilateral body atrophy and early age of onset. We report a 59-year-old woman with hemiatrophy of her face and upper limb on the left side presenting progressive hemiparkinsonism. Most of the HPHA patients have early age of onset, however, HPHA patients with age of onset over 50 years old have been reported. The clinical features of CBD are partly similar to those of HPHA, therefore it is important to consider HPHA as differential diagnosis of CBD even if the onset is late. In our patient, hemiatrophy was useful to differentiate HPHA from CBD. In previous reports, there was a difference between the dopamine D2 receptor binding capacity of CBD and that of HPHA. While the dopamine D2 receptor binding capacity of CBD was decreased asymmetrically, that of HPHA was not decreased. The PET finding of our patient revealed that asymmetrical reduction of [11C]-CFT uptake, meaning unilateral dopaminergic presynaptic hypofunction. However, [11C]-raclopride uptake, which assesses dopamine D2 receptor binding capacity, was normal. These PET findings are consistent with previous reports on HPHA. In our patient, hemiatrophy and PET findings were useful to diagnose HPHA.


Asunto(s)
Corteza Cerebral/patología , Hemiatrofia Facial/diagnóstico , Trastornos Parkinsonianos/diagnóstico , Atrofia , Diagnóstico Diferencial , Femenino , Lateralidad Funcional , Humanos , Imagen por Resonancia Magnética , Persona de Mediana Edad , Enfermedades Neurodegenerativas/diagnóstico , Tomografía Computarizada de Emisión de Fotón Único
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA